Translational research in oncology: Key bottlenecks and new paradigms

Expert Reviews in Molecular Medicine

Volumn 12, Issue , 2010, Pages

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CANCER LOCALIZATION; CANCER RESEARCH; CARCINOGENESIS; CLINICAL STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; MOLECULAR CLONING; MOLECULARLY TARGETED THERAPY; ONCOGENE; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; TRANSLATIONAL RESEARCH; TREATMENT PLANNING; DRUG DESIGN; GENETICS; MEDICAL RESEARCH; NEOPLASM; ONCOLOGY;

BIOMEDICAL RESEARCH; DRUG DESIGN; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 79952108766     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399410001638     Document Type: Review

References (47)

1. Jemal, A., Ward, E. and Thun, M. (2010) Declining death rates reflect progress against cancer. PLoS ONE 5, e9584
2. Sawyers, C.L. (2008) Translational research: are we on the right track? Journal of Clinical Investigation 118, 3798-3801
3. Nathan, D.G. and Varmus, H.E. (2000) The National Institutes of Health and clinical research: a progress report. Nature Medicine 6, 1201-1204
4. Sung, N.S. et al. (2003) Central challenges facing the national clinical research enterprise. Journal of the American Medical Association 289, 1278-1287 (Pubitemid 37432909)
5. Hawk, E.T. et al. (2008) The translational research workinggroupdevelopmentalpathways: introduction and overview. Clinical Cancer Research 14, 5664-5671
6. Marincola, F.M. (2003) Translational medicine: a two-way road. Journal of Translational Medicine 1, 1-2
7. Zerhouni, E.A. (2005) US biomedical research: basic, translational, and clinical sciences. Journal of the American Medical Association 294, 1352-1358
8. Druker, B.J. (2009) Perspectives on the development of imatinib and the future of cancer research. Nature Medicine 15, 1149-1152
9. Lydon, N. (2009) Attacking cancer at its foundation. Nature Medicine 15, 1153-1157
10. Stratton, M.R., Campbell, P.J. and Futreal, A.A. (2009) The cancer genome. Nature 458, 719-724
11. Workman, P. (2003) The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemotherapy Pharmacology 52, S45-S56
12. Weinstein, I.B. and Joe, A.K. (2006) Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nature Clinical Practice: Oncology 3, 448-457 (Pubitemid 44203817)
13. Sawyers, C.I. (2009) Shifting paradigms: the seeds of oncogenic addiction.Nature Medicine 15, 1158-1161
14. Knudson, A. (1971) Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Science 68, 820-823
15. Moolgavkar, S.H. (1986) Carcinogenesis modeling: from molecular biology to epidemiology. Annual Review of Public Health 7, 151-169
16. Zhang, X. and Simon, R. (2005) Estimating thenumberof rate-limiting genomic changes for human breast cancer. Breast Cancer Research and Treatment 91, 121-124 (Pubitemid 40684924)
17. Simon, R. and Zhang, X. (2008) On the dynamics of breast tumor development in women carrying germline BRCA1 or BRCA2 mutations. International Journal of Cancer 122, 1916-1917 (Pubitemid 351413444)
18. Armitage, P. and Doll, R. (1957) A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. British Journal of Cancer 11, 161-169
19. Loeb, L.A. (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Research 51, 3075-3079
20. Tomlinson, I. and Bodmer, W. (1999) Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nature Medicine 5, 11-12 (Pubitemid 29050986)
21. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57-70 (Pubitemid 30046295)
22. Beerenwinkel, N. et al. (2007) Genetic progression and thewaiting time to cancer. PLoS Computational Biology 3, 2239-2246 (Pubitemid 350241947)
23. Elenbaas, B. et al. (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes and Development 15, 50-65 (Pubitemid 32060682)
24. Sawyers, C.L. (2008) The cancer biomarker problem. Nature 452, 548-552
25. Pusztai, L. (2004) Perspectives and challenges of clinical pharmacogenomics in cancer. Pharmacogenomics 5, 451-454
26. Pusztai, L., Anderson, K. and Hess, K.R. (2007) Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clinical Cancer Research 13, 6080-6086 (Pubitemid 350075065)
27. Hess, K.R. et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer. Journal of Clinical Oncology 24, 4236-4244 (Pubitemid 46630780)
28. Simon, R. and Maitournam, A. (2005) Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 10, 6759-6763
29. Simon, R. and Maitournam, A. (2006) Evaluating the efficiency of targeted designs for randomized clinical trials: supplement and correction. Clinical Cancer Research 12, 3229 (Pubitemid 43837374)
30. Maitournam, A. and Simon, R. (2005) On the efficiency of targeted clinical trials. Statistics in Medicine 24, 329-339 (Pubitemid 40227650)
31. Hoering, A., LeBlanc, M. and Crowley, J. (2008) RandomizedphaseIII clinicaltrialdesigns fortargeted agents. Clinical Cancer Research 14, 4358-4367
32. Mandrekar, S. et al. (2005) Clinical trial designs for prospective validation of biomarkers. American Journal of Pharmacogenomics 5, 317-325 (Pubitemid 41425609)
33. Mandrekar, S. and Sargent, D. (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. Journal of Clinical Oncology 27, 4027-4034
34. Simon, R. (2008) Using genomics in clinical trial design. Clinical Cancer Research 14, 5984-5993
35. Simon, R. (2008) Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Reviewof Molecular Diagnostics 2, 721-729
36. Sargent, D.J. et al. (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 23, 2020-2027 (Pubitemid 46211382)
37. Mandrekar, S. and Sargent, D. (2009) Clinical trial designs for predictive biomarker validation: one size does not fit all. Journal of Biopharmaceutical Statistics 19, 530-542
38. Freidlin, B., McShane, L.M. and Korn, E.L. (2010) Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 102, 152-160
39. Pusztai, L. and Hess, K.R. (2004) Clinical trial design for microarray predictive marker discovery and assessment. Annals of Oncology 15, 1731-1737 (Pubitemid 40012239)
40. Zhou, X. et al. (2008) Bayesian adaptive design for targeted therapy development in lung cancer - a step towardpersonalized medicine.ClinicalTrials 5, 181-193
41. McShane, L.M., Hunsberger, S. and Adjei, A.A. (2009) Effective incorporation of biomarkers into phase II trials. Clinical Cancer Research 15, 1898-1905
42. Jiang, W., Freidlin, B. and Simon, R. (2007) Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 99, 1036-1043 (Pubitemid 47232604)
43. Freidlin, B. and Simon, R. (2005) Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11, 7872-7878 (Pubitemid 41611633)
44. Freidlin, B., Jiang, W. and Simon, R. (2010) The cross-validated adaptive signature design for predictive analysis of clinical trials. Clinical Cancer Research 16, 691-698
45. Simon, R. (2010) Clinical trials for predictive medicine: new challenges and paradigms. Clinical Trials Mar 25; [Epub ahead of print]
46. Simon, R.M., Paik, S. and Hayes, D.F. (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute 101, 1-7
47. Jones, S. et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806